ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,187.70
      0.13%
      US Tech 100
      17,618.80
      0.05%
      Dow Jones
      38,884.26
      0.08%
      Brent Oil
      82.50
      -0.44%
      Bitcoin
      62,464.01
      0.21%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Xenon Pharmaceuticals Inc (XENE)

      7. Xenon Pharmaceuticals Inc (XENE) News

      XENE

      Xenon Pharmaceuticals (XENE)

      Xenon Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:XENE
      DateTimeSourceHeadlineSymbolCompany
      12:51PMiHub NewswireFeaturedCannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa
      05/07/20244:01PMGlobeNewswire Inc.Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:XENEXenon Pharmaceuticals Inc
      05/02/20244:01PMGlobeNewswire Inc.Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
      04/16/20248:30AMGlobeNewswire Inc.Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual MeetingNASDAQ:XENEXenon Pharmaceuticals Inc
      04/04/20244:01PMGlobeNewswire Inc.Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:XENEXenon Pharmaceuticals Inc
      03/12/20244:01PMGlobeNewswire Inc.Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS DaysNASDAQ:XENEXenon Pharmaceuticals Inc
      03/08/20246:47PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
      03/08/20245:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
      03/08/20245:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
      03/08/20245:27PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
      03/07/20247:04PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
      03/07/20247:03PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
      03/05/20244:01PMGlobeNewswire Inc.Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024NASDAQ:XENEXenon Pharmaceuticals Inc
      02/29/20244:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
      02/29/20244:01PMGlobeNewswire Inc.Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
      02/22/20244:01PMGlobeNewswire Inc.Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
      02/14/20249:12AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XENEXenon Pharmaceuticals Inc
      01/08/20248:00AMGlobeNewswire Inc.Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024NASDAQ:XENEXenon Pharmaceuticals Inc
      01/03/20248:30AMGlobeNewswire Inc.Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:XENEXenon Pharmaceuticals Inc
      01/02/20244:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
      12/04/20234:16PMGlobeNewswire Inc.Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:XENEXenon Pharmaceuticals Inc
      12/02/202312:01PMGlobeNewswire Inc.Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)NASDAQ:XENEXenon Pharmaceuticals Inc
      11/30/20234:18PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:XENEXenon Pharmaceuticals Inc
      11/30/20234:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
      11/29/202310:51PMGlobeNewswire Inc.Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public OfferingNASDAQ:XENEXenon Pharmaceuticals Inc
      11/29/20235:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:XENEXenon Pharmaceuticals Inc
      11/29/20234:03PMGlobeNewswire Inc.Xenon Pharmaceuticals Announces Proposed Public OfferingNASDAQ:XENEXenon Pharmaceuticals Inc
      11/27/20237:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
      11/27/20237:00AMGlobeNewswire Inc.Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)NASDAQ:XENEXenon Pharmaceuticals Inc
      11/09/20234:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:XENE